The Hyderabad-based Bharat Biotech Ltd is confident about obtaining WHO’s emergency use listing.
Hyderabad-based Bharat Biotech has submitted 90 per cent of documents to World Health Organisation (WHO) for obtaining emergency use listing for the Covaxin, according to sources.
The remaining documents are expected to be submitted by June, the company told the Central government during a discussion on obtaining the WHO’s authorisation for emergency use listing for Covaxin, sources said.
The company is confident about obtaining WHO’s emergency use listing.
Sources also said that Covaxin received regulatory approval in 11 countries and interest from 11 companies in seven countries for technology transfer and production.
According to a report, the company is in the final stages of negotiations with the Food and Drug Administration of the US for conducting small-scale phase-III clinical trials of Covaxin in the United States.
